The Annual LifeSciences BC Salmon Barbecue has become one of LSBC's most popular events of the year.
With over 20 years' of history, this event offers our life sciences community the opportunity to enjoy a great meal in the company of 100+ peers in a breathtaking setting.
Event Details:
Date: Wednesday, June 19 2019
Time: 6:00 - 9:00 PM
Location:Cecil Green Park House
6251 Cecil Green Park Road, University of British Columbia
DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering
June 3, 2019 | VANCOUVER, British Columbia and MENLO PARK, Calif., |PRNewswire | -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct offering of an aggregate of 1,170,000 shares of common stock and, in a concurrent private placement, warrants to purchase 760,500 shares of common stock.
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2019 |VANCOUVER, British Columbia and MENLO PARK, Calif., | BRNewswire | - DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies presented clinical updates from the Company's ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme (GBM) at a key opinion leader (KOL) forum focused on brain tumors and the role of VAL-083 to address the unmet medical need in GBM during the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Touchless image navigation facilitates decision-making in the operating room
June 5, 2019 | Interventional News | A recent publication confirms "the utility of touchless image navigation in the sterile field in facilitating decision-making and resource allocation during endovascular procedures." The study, published in Minimally Invasive Therapy & Allied Technologies, provides the third clinical review of TIPSO technology (NZ Technologies), a human-computer interaction based platform that allows real-time access to imaging data in the sterile field.
NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future
jUNE 4, 2019 | Vancouver, BC | VDM Vascular Disease Management | NZ Technologies Inc. (NZTech) is pleased to announce the publication of the third clinical review this year of its TIPSO™ technology. The paper highlights TIPSO's ability to provide touchless control to physicians to access and manipulate radiology images in real time during image-guided medical procedures. This capability is enabled by a unique bedside interface designed for touchless interaction with patient images, obviating the need to delegate the task to an assistant, or unscrub and use an imaging workstation outside the sterile space.
Aspect Biosystems Partners With Merck, GSK, And Mcgill University To
Enable Development of Immuno-oncologu Therapeutics
Juen 4, 2019 | Vancouver, BC, Canada - Aspect Biosystems is proud to announce a collaboration with Merck, GSK, and McGill University's Goodman Cancer Research Centre. This $2.2M project is made possible by contributions from CQDM, the Canadian Cancer Society, Merck, GSK, Aspect Biosystems, and McGill University. These contributions underscore their commitment to driving innovation that will unlock the discovery of novel therapeutic targets and the development of immuno-oncology therapeutics.
Millions of dollars in funding announced for breast cancer research
B.C. shifting to cover cheaper 'biosimilar' drugs,
health minister says Social Sharing
U.S. Dental Implant and Final Abutment Market to Reach
$1.5 Billion by 2025 - New Study by iData Research
Sanofi, Regeneron dive deep on asthma in debut digital awareness campaign
health NEWS
FDA announces Project Facilitate to assist physicians seeking access to unapproved therapies for patients with cancer
June 3, 2019 | World Pharma News | Today, the U.S. Food and Drug Administration Oncology Center of Excellence announced a new pilot program to assist oncology health care professionals in requesting access to unapproved therapies for patients with cancer.
May 31, 2019 | World Pharma News | Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their doctors and a lingering stigma attached to the drug, according to researchers. The study, the first to look at how older Americans use cannabis and the outcomes they experience, was published this month in the journal Drugs & Aging.
How measles outbreak spurred renewed interest in national vaccine registry
June 3, 2019 | By Carolyn Ray | CBC News | Each province and territory has own immunization schedule, recording system |
As Colin Duggan and his wife were getting ready to take their 18-month-old daughter to get vaccinated, they realized they didn't know their own immunization history.
Over the years, Duggan has moved around, living in Nova Scotia, Ontario and the United States. When it came to finding his vaccination records, he was at a loss.
Program Manager - Scientific Communications - Histochemistry
As Scientists Helping Scientists, STEMCELL Technologies is dedicated to providing ongoing educational support to the scientific community via training courses, information resources, and other science communication services. STEMCELL Technologies is excited to have recently acquired http://stainsfile.info, a popular website for biomedical scientists seeking information on protocols, materials, and utilities of various chemical dyes and staining techniques.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates.
member
NEWS
IN THIS ISSUE
